Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy

Table 5 Multivariate analysis of OS association with clinical parameters

Clinical parameter	Multivariate analysis
	HR (95% CI)	P value
Tau expression	NS	NS
▪ negative
▪ positive
FIGO stage at diagnosis	NS	NS
○ Early (I,II)
○ Advanced (III,IV)
Histopathologic cell type	NS	NS
○ serous
○ others
Residual tumor size	NS	NS
○ <1 cm
○ > 1 cm
Sensitivity to first-line chemotherapy	22.59; 95% CI, 8.71-58.55	<0.0001
○ Resistant (<6 months)
○ Sensitive (>6 months)

ISSN: 1756-9966